neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Company profile
Ticker
CRNX
Exchange
Website
CEO
R. Scott Struthers
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CRNX stock data
Latest filings (excl ownership)
8-K
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
13 Sep 23
424B5
Prospectus supplement for primary offering
13 Sep 23
424B5
Prospectus supplement for primary offering
11 Sep 23
8-K
Regulation FD Disclosure
11 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
21 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
Transcripts
Latest ownership filings
SC 13G
Point72 Asset Management, L.P.
18 Sep 23
4
Richard Scott Struthers
16 Aug 23
4
Richard Scott Struthers
13 Jul 23
144
Notice of proposed sale of securities
13 Jul 23
144
Notice of proposed sale of securities
12 Jul 23
144
Notice of proposed sale of securities
11 Jul 23
4
Marc Wilson
21 Jun 23
4
Richard Scott Struthers
21 Jun 23
4
Coelho Rogerio Vivaldi
21 Jun 23
4
Caren Deardorf
21 Jun 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 40.85 mm | 40.85 mm | 40.85 mm | 40.85 mm | 40.85 mm | 40.85 mm |
Cash burn (monthly) | 547.00 k | 1.83 mm | 17.67 mm | 16.00 mm | 15.25 mm | 13.34 mm |
Cash used (since last report) | 1.65 mm | 5.51 mm | 53.21 mm | 48.19 mm | 45.92 mm | 40.20 mm |
Cash remaining | 39.21 mm | 35.35 mm | -12.35 mm | -7.34 mm | -5.07 mm | 657.76 k |
Runway (months of cash) | 71.7 | 19.3 | -0.7 | -0.5 | -0.3 | 0.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 141 |
Opened positions | 28 |
Closed positions | 15 |
Increased positions | 55 |
Reduced positions | 33 |
13F shares | Current |
---|---|
Total value | 944.36 bn |
Total shares | 58.35 mm |
Total puts | 21.10 k |
Total calls | 1.10 k |
Total put/call ratio | 19.2 |
Largest owners | Shares | Value |
---|---|---|
Driehaus Capital Management | 5.30 mm | $95.47 bn |
BLK Blackrock | 4.60 mm | $82.90 bn |
Orbimed Advisors | 3.95 mm | $71.19 bn |
Wellington Management | 3.60 mm | $64.90 bn |
Biotechnology Value Fund L P | 2.74 mm | $0.00 |
Vanguard | 2.73 mm | $49.24 bn |
Bain Capital Life Sciences Investors | 2.31 mm | $41.55 bn |
STT State Street | 2.24 mm | $40.32 bn |
Perceptive Advisors | 1.95 mm | $35.08 bn |
First Light Asset Management | 1.56 mm | $28.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Aug 23 | Struthers Richard Scott | Common Stock | Option exercise | Acquire M | No | No | 1.91 | 10,000 | 19.10 k | 135,522 |
14 Aug 23 | Struthers Richard Scott | Incentve stock option Common Stock | Option exercise | Dispose M | No | No | 1.91 | 10,000 | 19.10 k | 151,270 |
13 Jul 23 | Struthers Richard Scott | Common Stock | Sell | Dispose S | Yes | No | 20.35 | 14,157 | 288.09 k | 630,805 |
12 Jul 23 | Struthers Richard Scott | Common Stock | Sell | Dispose S | Yes | No | 20.17 | 11,459 | 231.13 k | 644,962 |
11 Jul 23 | Struthers Richard Scott | Common Stock | Sell | Dispose S | Yes | No | 20.14 | 24,384 | 491.09 k | 656,421 |
20 Jun 23 | Marc Wilson | Common Stock | Sell | Dispose S | No | No | 19.97 | 20,000 | 399.40 k | 95,158 |
20 Jun 23 | Marc Wilson | Common Stock | Option exercise | Acquire M | No | No | 9.28 | 20,000 | 185.60 k | 115,158 |
20 Jun 23 | Marc Wilson | Common Stock | Sell | Dispose S | No | No | 19.96 | 10,922 | 218.00 k | 95,158 |
20 Jun 23 | Marc Wilson | NQSO Common Stock | Option exercise | Dispose M | No | No | 9.28 | 20,000 | 185.60 k | 71,185 |
16 Jun 23 | Fust Matthew K | Common Stock | Grant | Acquire A | No | No | 0 | 6,000 | 0.00 | 18,536 |
News
Top 4 Health Care Stocks That Should Keep You Up At Night
21 Sep 23
HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $33 Price Target
14 Sep 23
What's Going On With Crinetics Pharmaceuticals Stock?
12 Sep 23
Crinetics Pharmaceuticals Plans Proposed Public Offering Of $250M Of Common Stock
11 Sep 23
Nasdaq Rises Over 1%; Hostess Brands Shares Spike Higher
11 Sep 23
Press releases
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
20 Sep 23
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
12 Sep 23
Thinking about trading options or stock in Tesla, C3.ai, Macy's, Crinetics Pharmaceuticals, or Tractor Supply?
12 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
11 Sep 23
Thinking about trading options or stock in Crinetics Pharmaceuticals, Tesla, Rtx Corp, Palantir Technologies, or Amazon.com?
11 Sep 23